Disclosure NewswireTMiCrowdNewswire - Nov 3, 2017
Pine Brook, New Jersey – 2 November 2017. Alvogen is first to market and has received final approval for the generic equivalent to Tamiflu® (oseltamivir phosphate) 6 mg/ml powder for oral suspension in the United States. In December 2016, Alvogen launched the first generic equivalent to Tamiflu® (oseltamivir phosphate) capsules in the United States.
Annual sales for Oseltamivir suspension amount to $312 million in the U.S. market, based on IMS Midas data.
Robert Wessman, Chairman and CEO of Alvogen, commented: “The approval and launch of Alvogen’s oseltamivir phosphate powder for oral suspension is great news for U.S. patients, who will have access to a more affordable alternative. Alvogen is one of the fastest growing pharmaceutical companies in the U.S. market and this launch further demonstrates our ability to be first to market with new generic alternatives for U.S. patients.”
Alvogen currently has 75 products in development and pending FDA approval for the U.S. market. Annual brand sales for filed products and those under development have current brand sales exceeding $25 billion, according to IMS Health (2015). *Tamiflu is a registered trademark of Hoffman La-Roche Inc. Corporation.
Global Corporate Marketing & Communications
Tel: (+354) 522 2900
Email: [email protected]
About Alvogen Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter medicines (OTC) and biosimilar products for patients around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China. Learn more about Alvogen on www.alvogen.com